Biocius strikes Japanese distribution deal
Spectrometry device maker Biocius Life Sciences Inc. reports it is expanding into Asia, after striking a distribution agreement with Japanese manufacturer Wako Pure Chemicals Ltd.
Under the deal, Wako will distribute Biocius’ RapidFire high-throughput mass spectrometry system in Japan. Wako will also provide Biocius’ contract research services and in vitro ADME screening applications to the Japanese market.
Woburn-based Biocius’ RapidFire product is a spectrometry-based drug discovery screening device intended to make drug discovery more efficient for researchers.
Biocius spun itself out from Woburn-based BioTrove Inc. in December 2009, a month after its formation. The company was spun out to hold BioTrove’s RapidFire intellectual property separate from Carlsbad, Calif.-based Life Technologies Corp. (Nasdaq: LIFE), which acquired BioTrove last year.
Biocius, led by chairman and CEO Jeffrey Leathe, the former chief financial officer of BioTrove, lists its backers as Catalyst Health Ventures, Excel Venture Management, Fletcher-Spaght, CB Health Ventures, Vox Equity Partners, Echelon Ventures and BioFrontier Partners